SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000929638-24-000387
Filing Date
2024-02-06
Accepted
2024-02-06 17:26:45
Documents
2
Group Members
JEFF EASTONLIND GLOBAL ASSET MANAGEMENT V, LLCLIND GLOBAL PARTNERS II LLC

Document Format Files

Seq Description Document Type Size
1 sch13g.htm SC 13G 71838
2 JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS exhibit99-1.htm EX-99.1 7769
  Complete submission text file 0000929638-24-000387.txt   81509
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Subject) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-53409 | Film No.: 24601326
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022 646-701-7428
Lind Global Fund II LP (Filed by) CIK: 0001871665 (see all company filings)

IRS No.: 863914253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G